Seattle, United States
Key Proteo, Inc., founded in 2019, is making strides in the Health Care and Medical Devices industries. Based in the United States, the company is committed to "Changing the Clinical Course of Treatable Rare Genetic Disorders" through cutting-edge proteomic analysis.
Initially focusing on newborns, Key Proteo aims to democratize the early detection of rare but treatable genetic disorders. By identifying extremely low abundance protein biomarkers previously considered undetectable, the company offers a novel approach to newborn screening. Early intervention for such disorders can potentially alter their clinical outcomes, fulfilling the company’s mission to alleviate patient suffering and save lives.
In a recent development, Key Proteo secured a $3.03M Seed Round investment on 16 May 2023, signaling confidence in its potential from the investment community. The capital will likely support the expansion of their screening technologies and mission-driven projects. This company presents a compelling opportunity for investors seeking innovation in genetic disorder diagnostics.
